It also remarkably decreased the level of hs-crp (MD = −6.50, 95% CI [−7.79, −5.21], P < .00001), enhanced ADL (MD = 20.38, 95% CI [17.98, 22.79], P < .00001), and alleviated hematoma and edema (MD = −2.53, 95% CI [−4.75, −0.31] P < .05; MD = −1.74 95% CI [−2.42, −1.07] P < .00001) compared with conventional treatment. Here, CRP is linked to hematoma.